Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICAIT DC Vaccine
- Development stage
- Unknown
- Lead developer
- ImmunoRestoration
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
The ICAIT DC Vaccine is an autologous dendritic cell-based immunotherapy developed by ImmunoRestoration for the treatment of HER-2-positive ductal carcinoma in situ (DCIS). Utilizing the proprietary ICAIT™ (Immune Conditioning via Activated Innate Transfer) platform, the therapy involves harvesting a patient's own dendritic cells and pulsing them with HER-2 peptide antigens. These activated cells are then re-administered to the patient to prime and stimulate a HER-2-specific T-cell immune response. The vaccine targets HER-2/neu over-expression, which plays a critical role in the progression from DCIS to invasive breast cancer. Clinical studies have demonstrated the vaccine's ability to eliminate HER-2 expression in DCIS lesions and induce pathologic complete responses.
- Other names
- ICAIT dendritic cell vaccineHER-2 pulsed dendritic cell vaccineHER2 pulsed dendritic cell vaccineHER 2 pulsed dendritic cell vaccineImmunoRestoration HER-2 DC vaccine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ICAIT DC Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICAIT DC Vaccine.